Drug Makers And Payers To Blame For Biosimilar Barriers In U.S. Market

Biosimilars are gradually making inroads in the outpatient drug market in the U.S., But Stelara-referenced biosimilars appear to be following the convoluted path that Humira-referenced biosimilars took, with payers and pharmacy benefit managers playing critical roles in terms of market or patient access. The cheapest versions are not necessarily favored.

getty